Trial Profile

A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a proton pump inhibitor in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Xevinapant (Primary) ; Pantoprazole
Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
Focus Pharmacodynamics; Pharmacokinetics

Most Recent Events

07 Jun 2024 New trial record
10 Apr 2024 Results assessing the effect of high gastric pH on bioavailability of xevinapant presented at the 115th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com